Journal of Nanobiotechnology · 2025 · 10 citations · 20 references
Life SciencesMolecular BiologyOncologyGenome EditingMolecular Cell BiologyMolecular OncologyCancer Cell SignalingCancer GenomicsCrispr-cas SystemsOncogenic Signaling PathwaysTargeted Cancer TherapyBreast Cancer Resistance MechanismsCrispr-cas9 Genome EditingGenome-wide Crispr ScreeningHormone Receptor - Positive Breast CancerPrecision Oncology Target DiscoveryTargeted Resistance Mechanisms
CDK4/6i, the first-line drug for treating ERα-positive breast cancer, significantly improves clinical outcomes. However, CDK4/6i resistance often develops and remains a major hurdle, and the underlying mechanisms remain challenging to fully investigate. Here, we used Genome-wide CRISPR/Cas9 library screening combined with single-cell sequencing to screen for molecules mediating CDK4/6i resistance and identified METTL14 as a determinant of CDK4/6i sensitivity. Clinical samples and datasets were analyzed and in vitro and in vivo experiments were performed to confirm the critical function of METTL14 in CDK4/6i resistance. Mechanistically, METTL14 can induce an increase in E2F1 expression in breast cancer cells via an m6A IGF2BP2-dependent mechanism and thus promote CDK4/6i resistance. Furthermore, through a small molecule screen, a novel METTL14 inhibitor named WKYMVM, which can restore sensitivity to CDK4/6i in CDK4/6i-resistant breast cancer cells, was identified. Treatment with folate-conjugated liposomes targeting breast cancer cells that contained both a CDK4/6i and WKYMVM revealed the synergistic effect of METTL14 inhibition with CDK4/6i therapy in a CDK4/6i-resistant PDX model. Together, our findings reveal the mechanism of CDK4/6i resistance and provide a strategy for overcoming CDK4/6i resistance via METTL14 inhibition.
20
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Structural basis of N6-adenosine methylation by the METTL3–METTL14 complex
Xiang Wang, Jing Feng, Yuan Chao Xue et al. · Nature · 2016 · 1.2K citations
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Jinfang Zhang, Xia Bu, Haizhen Wang et al. · Nature · 2017 · 1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano, Yao Lu, Alberto Servetto et al. · Nature Communications · 2019 · 419 citations · Full text
Medicine, Oncology, Pharmacology +17